The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in ...
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (OVID) (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results